Strategic Partner(s)

Dr. Arun Shukla: How Two Arrestins Regulate 800 GPCRs

The human genome encodes more than 800 GPCRs — and just two beta-arrestin isoforms to regulate their signaling, endocytosis, and degradation. How two structurally similar proteins orchestrate such functional diversity across an entire receptor superfamily remains one of pharmacology's most stubborn unsolved problems.

Dr. Arun Shukla's lab at the Indian Institute of Technology, Kanpur attacks this question from multiple angles: structural snapshots by cryo-EM and crystallography, dynamic information from NMR and hydrogen-deuterium exchange, and custom-engineered antibody fragments that both stabilize transient complexes and report on their conformations in live cells. His team also works on so-called non-canonical GPCRs — receptors once dismissed as non-functional because they don't couple to G proteins — and has helped establish that these are, in effect, nature's own beta-arrestin-biased receptors.

For Dr. Shukla, the question of how two proteins manage 800 others isn't abstract — it's the one that pulled him back from Lefkowitz's lab at Duke to build a structural pharmacology program from the ground up in India.

About the Guest

Dr. Arun Shukla leads a structural pharmacology lab in the Department of Biological Sciences and Bioengineering at the Indian Institute of Technology, Kanpur. His research focuses on the structural and functional basis of GPCR–beta-arrestin interactions, combining cryo-electron microscopy, X-ray crystallography, NMR, hydrogen-deuterium exchange, and engineered antibody fragments to resolve how beta-arrestins recognize and regulate a diverse receptor family. He completed his PhD at the Max Planck Institute of Biophysics in Frankfurt and postdoctoral training in Bob Lefkowitz's lab at Duke University before returning to India in 2014. Among his lab's contributions are antibody-based intrabodies that inhibit receptor endocytosis in live cells and biosensors that visualize beta-arrestin conformations across multiple receptor systems.

Scientific Themes of the Conversation

The structural and functional basis of GPCR–beta-arrestin coupling
How two beta-arrestin isoforms regulate an 800-member receptor family
Non-canonical GPCRs as physiological beta-arrestin-biased receptors
Engineered antibody fragments as tools for structural stabilization and live-cell conformational reporting
The limits and promise of biased agonism in drug discovery
Methodological triangulation — pairing static structures with dynamic measurements and cellular validation

Key Insights from the Conversation

Two proteins, eight hundred receptors The central puzzle driving Dr. Shukla's lab is also one of the field's oldest open questions: how do just two beta-arrestin isoforms, structurally nearly identical, mediate the signaling, endocytosis, and ubiquitination of over 800 distinct GPCRs? The answer lies somewhere in the diversity of receptor architectures — long C-termini versus long ICL3s, phosphorylation patterns, and a conformational flexibility arrestins must dynamically adapt to.

The "non-functional" GPCRs were never non-functional Receptors like CXCR7, C5L2, and TQIP6 were long dismissed as non-canonical because they don't couple to G proteins. Dr. Shukla's lab and others have shown they signal robustly through beta-arrestins — which makes them, in effect, physiological examples of the beta-arrestin-biased receptors pharmacologists have been trying to design from scratch.

Biased agonism is harder than the opioid story suggested The neat bifurcation between G-protein and beta-arrestin signaling that drove early opioid receptor drug design has not held up cleanly in subsequent studies. Cell context, assay choice, and receptor conformational heterogeneity all contribute to outcomes. The concept remains powerful, but it demands better tools and more careful interpretation than the field initially assumed.

An antibody built for one job that did another Dr. Shukla's lab designed antibody fragments to stabilize GPCR–beta-arrestin complexes for structural studies. One of them did the opposite: it disrupted the beta-arrestin–clathrin interaction and became a generic inhibitor of receptor endocytosis. The team kept it. That moment of unplanned utility is a recurring theme in his lab.

One biosensor, conserved structure and hidden diversity An intrabody raised against the active conformation of beta-arrestin-1 bound to the vasopressin receptor tail was expected to be receptor-specific. It wasn't. It recognized beta-arrestin-1 complexes for the neurotensin and complement C5a receptors — but not every GPCR. That selective cross-reactivity turned the reagent into a visual probe of which receptor-arrestin pairs share a conformational fingerprint and which don't.

The moment research stopped being a question During his master's at JNU, Dr. Shukla wasn't sure research would be his career. Then he started his thesis project and found himself skipping theory classes to be in the lab. That's when the question answered itself. For many scientists, the origin moment is this ordinary and this decisive.

What a one-line email to Bob Lefkowitz can do Toward the end of his PhD in Frankfurt, Dr. Shukla wrote to Bob Lefkowitz at Duke — no formal interview, no rotation, just a CV and a short note. Lefkowitz invited him. It's a small correction to the assumption that elite postdocs require elaborate application rituals.

Episode Timeline

00:00 Introduction
02:15 From DNA quadruplexes to GPCR structural biology
06:32 The master's project that made research a career
08:35 The puzzle — two arrestins, 800 GPCRs
14:29 Antibody fragments, intrabodies, and biosensors
21:09 Non-canonical GPCRs as nature's own biased receptors
23:43 When biased agonism got complicated
38:55 The intrabody they didn't mean to make
43:36 Building a more diverse GPCR community
49:47 Running a lab in India through the pandemic

Timestamps were generated using AI for readability.

Selected Quotes

"There are more than 800 GPCRs, as you know, but there are only two isoforms of beta-arrestins. They're structurally very similar, but they can have quite a significant degree of functional divergence. The key question that continues to fascinate us is how two isoforms of beta-arrestins are able to interact with such a large repertoire of GPCRs and regulate their function."

"I was not, to be honest, sure if research was what I wanted to take up as a career. But once I started working in a research lab for my master's thesis, I loved it so much that I would miss my theory classes to work in the lab. That is where I realized research is what I want to do for the rest of my life."

"One name that kept popping up was Bob Lefkowitz. I wrote an email to him. No formal interview, nothing of that sort. I just shared my CV, and he invited me."

"Initially we thought — I personally thought — that this is not what we want. But then later we realized in the lab that even if it is not what we want, it can be used for other things."

About this episode

In this episode of the Dr.GPCR podcast, my guest is Dr. Arun Shukla from the Indian Institute of Technology in Kanpur, India. Arun is currently an Associate Professor & Joy Gill Chair Professor, Intermediate Fellow, Wellcome Trust DBT India Alliance

Swarnajayanti Fellow & EMBO Young Investigator at the Department of Biological Sciences and Bioengineering. He earned his master's degree in biotechnology from Jawaharlal Nehru University in India and it was during a biochemistry class where he learned about cell signaling that he became curious and wanted to learn more about it. Arun first started working on GPCRs and their structural characterization at the Max Planck Institute of Biophysics where he completed his doctoral studies in the lab of Dr. Hartmut Michel.

Fascinated by GPCRs he wrote to Dr. Bob Lefkowitz and asked him if he could join his lab at Duke University. Dr. Shukla spent several years in the Lefkowitz lab and collaborated extensively with Dr. Brian Kolbika of Stanford University.

Join us and learn more about Dr. Shukla’s research and how working in the lab instead of going to classes made him realize that research is what he wants to do for the rest of his life.

Dr. Arun Shukla on the web